This review provides an overview of the clinical application, pharmacokinetics, and safety considerations of dabigatran etexilate in specific populations.
Requires individualized assessment of bleeding risk, age, renal function, and interactions with dabigatran; leaves open need for prospective validation in special populations.
BACKGROUND: Dabigatran etexilate (DE) was approved by the FDA in 2010 to reduce the risk of stroke and systemic embolism in adults with Non-valvular Atrial Fibrillation (NVAF). Compared with warfarin, a traditional anticoagulant drug, DE exhibits a shorter half-life, improved dose-effect relationship, fewer food and drug interactions, and can be taken orally without monitoring the conventional coagulation index. DE can also prevent or reduce the severity of adverse events, such as attenuated drug efficacy or bleeding. It is convenient for patients to take DE due to low levels of individual variation. This review aims to application of Dabigatran etexilate in specific populations. METHODS: Fifty-five papers were included in the review. RESULTS: We review the pharmacological mechanisms, pharmacokinetics and drug interactions, as well as the application of DE for different clinical populations, and provide clinical guidelines. CONCLUSION: When using DE, one should consider the risk of bleeding, age, renal function, drug interactions, and other factors.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: